Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection

NCT03853369 is registered in ClinicalTrials.gov with Sichuan Baili Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03853369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03853369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection
Lead sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
February 18, 2019
Completion date
December 30, 2019
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ventricular fibrillation, ventricular tachycardia